Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20CD3 bispecific antibody, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma

CONCLUSIONS: This biomarker analysis expands on clinical findings of odronextamab in patients with R/R B-NHL, providing verification of the suitability of CD20 as a therapeutic target, as well as evidence for potential mechanisms of action and …